Pasireotide
Treatment for Cushings Syndrome
Typical Dosage: 600-900 mcg BID (injectable) or 10-40 mg IM every 28 days (LAR)
Effectiveness
25%
Safety Score
55%
Clinical Trials
5
Participants
500
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
600-900 mcg BID (injectable) or 10-40 mg IM every 28 days (LAR)
Time to Effect
1-3 months
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4.5(Treat 4.5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1.5(Treat 1.5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150,000
Monitoring:$2,500
Side Effect Mgmt:$2,000
Total Annual:$154,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$550,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$618,000
Cost per Remission
$618,000
Pasireotide Outcomes
for Cushings Syndrome
Efficacy Outcomes
Overall Effectiveness
+25%
Response Rate
+25%
Remission Rate
+25%
Common Side Effects
Hyperglycemia (often leading to diabetes)
+75%
Diarrhea/Nausea
+50%
Abdominal pain
+25%
Gallstones
+15%
Bradycardia
+8%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
2 completed trials for Pasireotide in Cushings Syndrome
A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
NCT00088608COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Los Angeles, United States +4 more
Started: Apr 1, 2004
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
NCT01374906COMPLETEDPHASE3
150 participants
INTERVENTIONAL
Phoenix, United States +81 more
Started: Nov 4, 2011